NDAQ:APHA - Post Discussion
Aphria Inc.
> APHA ANNOUNCES SUPPLY AGREEMENT EU/MATERIA DEUTCHLAND
Post by
Humanist on Feb 23, 2021 7:23am
APHA ANNOUNCES SUPPLY AGREEMENT EU/MATERIA DEUTCHLAND
APHRIA’S SUBSIDIARY CC PHARMA ANNOUNCES MAJOR EUROPEAN SUPPLY AGREEMENT
FEB 23, 2021/ 7:06 AM Materia, a medical cannabis and wellness company focused on the European market, is pleased to announce that its wholly-owned subsidiary Materia Deutschland GmbH, is expanding its portfolio of medical cannabis products being offered to pharmacies acrossGermany.
Materia Deutschland has entered into a commercial supply agreement with CC Pharma GmbH (” CC Pharma “), a wholly owned subsidiary of Aphria Inc., to distribute its high quality, Aphria-branded flower products across Materia Deutschland’s pharmacy network throughout Germany . Under the terms of this agreement, CC Pharma will import and batch release the products, with Materia Deutschland taking responsibility for pharmacy sales and fulfillment.
Separately, Materia Deutschland has also entered into an agreement with an EU-GMP certified supplier of dronabinol, a pure THC API that accounts for approximately 35% of all publicly reimbursed medical cannabis prescriptions in Germany 1 , including finished pharmaceuticals.
“We have been intentionally selective in growing our portfolio, to ensure that new products will satisfy patients’ evolving needs and bear the highest standards of quality,” said Sebastian Blte, Managing Director, Germany , of Materia Deutschland. “We are proud to work with partners who share our unwavering commitment to patient care and an enhanced societal understanding of cannabis’ medical potential.”
The addition of Aphria flower and dronabinol will bolster Materia Deutschland’s offering to customers and accelerate its growth potential in the German market. Materia has already commenced sales of dronabinol, while sales of Aphria-branded products to pharmacies will begin in the coming weeks. | ________________ |
| 1 GKV-Spitzenverband |
About Materia
Materia’s vision is to be the enabler of global cannabis access. Materia is developing a robust pharmaceutical manufacturing and distribution ecosystem to grow the legal cannabinoid market across Europe . With its research-driven team and regulatory expertise, Materia focuses on the high-margin downstream activities of processing, formulation and distribution into markets wherever there is a patient in need of cannabis medicine or CBD consumers seeking innovative new products.
Be the first to comment on this post